Healthdirect Australia is not responsible for the content and advertising on the external website you are now entering.
Brand name: COVID-19 ChAdOx1-S Viral Vector Vaccine (AstraZeneca) TM
Active ingredients: covid-19 viral vector vaccine
On May 30, 2024 COVID-19 ChAdOx1-S Viral Vector Vaccine (AstraZeneca) was not listed on the Australian Register of Therapeutic Goods (ARTG).
Healthdirect medicine data is refreshed once a month, see Data sources page. The medicine you searched for may have been added to the ARTG after this date.
Ask your pharmacist, doctor or health professional for advice, or search the ARTG.
Is this medicine available in Australia?
The ARTG is the register of all therapeutic goods that can be lawfully supplied in Australia. Sometimes a special provision is made to make available some medicines that are not listed in response to the needs of particular people or circumstances. To find out more check out the "Access to therapeutic goods not on the ARTG" section on the ARTG page.
Other medicines that contain: covid-19 viral vector vaccine
Need more information?
These trusted information partners have more on this topic.
Top results
Vaxzevria (AstraZeneca) vaccine and thrombosis with thrombocytopenia (TTS) | Australian Government Department of Health and Aged Care
Thrombosis with thrombocytopenia (TTS) is a rare syndrome that occurred in around 2 to 3 people per 100,000 who were vaccinated with AstraZeneca. AstraZeneca is no longer available in Australia from 21 March 2023.
Read more on Australian Government Department of Health and Aged Care website
Frequently Asked Questions about COVID-19 vaccines for people affected by cancer | Cancer Australia
Cancer Australia has compiled answers to Frequently Asked Questions (FAQs) about COVID-19 vaccines for people affected by cancer based on information and evidence currently available in Australia and internationally.
Read more on Cancer Australia website
COVID-19 vaccination when pregnant or breastfeeding and for those planning pregnancy - RANZCOG
The Royal Australian and New Zealand College of Obstetricians and Gynaecologists (RANZCOG) acknowledges the risk posed to the community, healthcare workers, and all patients, due to the COVID-19 (coronavirus) pandemic
Read more on RANZCOG - Royal Australian and New Zealand College of Obstetricians and Gynaecologists website
Top results
COVID-19 vaccination when pregnant or breastfeeding and for those planning pregnancy - RANZCOG
The Royal Australian and New Zealand College of Obstetricians and Gynaecologists (RANZCOG) acknowledges the risk posed to the community, healthcare workers, and all patients, due to the COVID-19 (coronavirus) pandemic
Read more on RANZCOG - Royal Australian and New Zealand College of Obstetricians and Gynaecologists website
COVID-19 vaccines and cardiac inflammation | Australian Government Department of Health and Aged Care
Cases of myocarditis and pericarditis after COVID-19 vaccines are rare: mostly reported in males under 40 years of age, after the second dose. Cases do occur in both females and males, at any age, and after any dose, including a third or fourth dose. Most cases are mild and patients recover quickly.
Read more on Australian Government Department of Health and Aged Care website
